Patent
Anti-angiogenic compositions and methods of use
William L. Hunter,Lindsay S. Machan,A. Larry Arsenault +2 more
- 19 Jul 1994
1.2K
TL;DR: In this article, an anti-angiogenic factor and a polymeric carrier were used for embolization of blood vessels and eliminating biliary, urethral, esophageal, and tracheal/bronchial obstructions.
read more
Abstract: The present invention provides compositions comprising an anti-angiogenic factor, and a polymeric carrier. Representative examples of anti-angiogenic factors include Anti-Invasive Factor, Retinoic acids and derivatives thereof, and paclitaxel. Also provided are methods for embolizing blood vessels, and eliminating biliary, urethral, esophageal, and tracheal/bronchial obstructions.
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
Patent
Coated implantable medical device
Brian L. Bates,Anthony O. Ragheb,Neal E. Fearnot,Thomas G. Kozma,William D. Voorhees +4 more
- 31 Oct 2007
TL;DR: A coated implantable medical device as discussed by the authors includes a structure 12 adapted for introduction into the vascular system, esophagus, trachea, colon, biliary tract, or urinary tract.
1.8K
Patent
Therapeutic inhibitor of vascular smooth muscle cells
Lawrence L. Kunz,Peter G. Anderson +1 more
- 15 Feb 1996
TL;DR: In this paper, the authors present methods for the direct and/or targeted delivery of therapeutic agents to vascular smooth muscle cells that cause a dilation and fixation of the vascular lumen by inhibiting smooth muscle cell contraction, thereby constituting a biological stent.
1K
Patent
Medical devices and applications of polyhydroxyalkanoate polymers
Simon F. Williams,David P. Martin,Frank A. Skraly +2 more
- 24 Mar 2000
TL;DR: In this paper, the degradation times of polyhydroxyalkanoates are controlled under physiological conditions, and the degradation rates are controlled with less than one year under certain physiological conditions.
1K
Patent
Silver implantable medical device
Anthony O. Ragheb,Brian L. Bates,Neal E. Fearnot,Thomas A. Osborne,Thomas G. Kozma,Joseph W. Roberts,William D. Voorhees +6 more
- 23 Oct 1997
TL;DR: In this paper, a coronary stent implantable medical device is defined as a structure 12 adapted for introduction into the vascular system, esophagus, trachea, colon, biliary tract, or urinary tract.
900
Patent
Drug coating with topcoat
Ni Ding,Michael N. Helmus +1 more
- 19 Jun 1998
TL;DR: In this paper, a method for a coating an implantable device or prosthesis is described, which includes an undercoat of polymeric material containing an amount of biologically active material, particularly heparin, dispersed therein.
850
References
Patent
Anti-angiogenic stents and methods of their preparation
Helen M. Burt,William L. Hunter,Lindsay S. Machan,A. Larry Arsenault +3 more
- 19 Jul 1994
TL;DR: In this article, an anti-angiogenic factor and a polymeric carrier were proposed for embolization of blood vessels and eliminating biliary, urethral, esophageal, and tracheal/bronchial obstructions.
6
INTERACTION OF PROTEIN SUBSTRATE AND INHIBITORS WITH α2-MACROGLOBULIN-BOUND PROTEINASES
TL;DR: This work attempts to quantify the interaction between a,M-bound trypsin and chymotrypsinogen, a protein substrate for which the kinetic parameters k,,, and K, can be measured and whether or not the a, M-induced decrease in proteinase-inhibitor affinity depends upon the size of the inhibitor as is usually believed.
6
Effects of prolonged antitubulin culture on the ultrastructure of anterior limb bud cells of the chick embryo.
Richard G. Kessel,Hideki Katow +1 more
TL;DR: The results indicate that prolonged culture of cells in antitubulins need not, in itself, lead to a condition of enhanced AL development as reported in several other studies using various cell types.
5
793-4 Local Delivery of C-myb Antisense attenuates Neo-Intimal Thickening in a Porcine Model of Coronary Angioplasty
Julian Gunn,Cathy M. Holt,L Shepherd,Sheila E. Francis,Geoffrey H. Smith,David C. Cumberland +5 more
TL;DR: Ex vivo and in vivo delivery of fluorescein labelled oligonucleotide using this system demonstrated successful intramural localisation and a consistent reduction in absolute and percent intimal thicknesses and areas together with a significant reduction in mean intimal/medial thickness ratio.
5
Related Papers (5)
Ni Ding,Michael N. Helmus +1 more
- 19 Jun 1998
Eric P. Berg,Ronald J. Tuch,Michael Dror,Rodney G. Wolff +3 more
- 07 Jun 1995